{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:27:14Z","timestamp":1787164034450,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In evaluation of systemic lupus erythematosus (SLE), anti\u2013double-stranded DNA antibodies (anti-dsDNA) play a significant role in diagnosis, monitoring SLE activity, and assessing prognosis. However, evaluations of the performance and limitations for recently developed methods for anti-dsDNA assessment are sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Specimens used for antinuclear antibody testing (n = 129) were evaluated for anti-dsDNA assay comparability across 4 medical centers in the United States. The methods compared were Werfen Quanta Lite dsDNA, Zeus Scientific dsDNA Enzyme Immunoassay, Bio-Rad multiplex immunoassay (MIA) dsDNA, ImmunoConcepts Crithidia, and Bio-Rad Laboratories Crithidia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For quantitative anti-dsDNA measurements, Spearman\u2019s correlation coefficient was highest between Zeus and Werfen (\u03c1 = 0.86; CI, 0.81-0.90; P &amp;lt; .0001). Comparison of MIA to Werfen or Zeus yielded similar results to each other (\u03c1 = 0.58; CI, 0.44-0.68; P &amp;lt; .0001; and \u03c1 = 0.59; CI, 0.46-0.69; P &amp;lt; .0001, respectively), but lower than the correlation between Zeus and Werfen. Positive concordance between assays ranged from 31.4% to 97.1%, and negative concordance between assays ranged from 58.5% to 100%. The detection of anti-dsDNA in those with SLE diagnosis ranged from 50.9% to 77.4% for quantitative assays and 15.1% to 24.5% for Crithidia assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current quantitative anti-dsDNA assays are not interchangeable for patient follow-up. Crithidia-based assays demonstrate high negative concordance and lack positive concordance among the methods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/labmed\/lmae035","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T23:56:51Z","timestamp":1714435011000},"page":"732-738","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of quantitative and qualitative anti-dsDNA assays"],"prefix":"10.1093","volume":"55","author":[{"given":"Rajeevan","family":"Selvaratnam","sequence":"first","affiliation":[{"name":"Laboratory Services, BayCare Health System , Tampa, FL ,","place":["US"]},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-7908","authenticated-orcid":false,"given":"Danyel H","family":"Tacker","sequence":"additional","affiliation":[{"name":"Department of Pathology, Anatomy, and Laboratory Medicine, School of Medicine, West Virginia University , Morgantown, WV ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Thebo","sequence":"additional","affiliation":[{"name":"Central Pennsylvania Alliance Laboratory , York, PA ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7851-9836","authenticated-orcid":false,"given":"Sarah E","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["US"]},{"name":"Department of Pathology, School of Medicine, University of Pittsburgh , Pittsburgh, PA ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"issue":"1","key":"2024110408205547400_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.91.1.1","article-title":"Localization of antigen in tissue cells","volume":"91","author":"Coons","year":"1950","journal-title":"J Exp Med."},{"issue":"8","key":"2024110408205547400_CIT0002","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"9","key":"2024110408205547400_CIT0003","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2024110408205547400_CIT0004","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar3258","article-title":"Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden","volume":"13","author":"Eriksson","year":"2011","journal-title":"Arthritis Res Ther."},{"issue":"16","key":"2024110408205547400_CIT0005","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med."},{"issue":"1","key":"2024110408205547400_CIT0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Agmon-Levin","year":"2014","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"2024110408205547400_CIT0007","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"2024110408205547400_CIT0008","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/annrheumdis-2017-211814","article-title":"Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)","volume":"76","author":"Ugarte-Gil","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2024110408205547400_CIT0009","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kew377","article-title":"Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus","volume":"56","author":"Tsang-A-Sjoe","year":"2016","journal-title":"Rheumatology"},{"issue":"1","key":"2024110408205547400_CIT0010","doi-asserted-by":"crossref","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Medicine."},{"issue":"6","key":"2024110408205547400_CIT0011","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"2024110408205547400_CIT0012","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"2024110408205547400_CIT0013","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/keu406","article-title":"The clinically quiescent phase in early-diagnosed SLE patients: inception cohort study","volume":"54","author":"Kasitanon","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2024110408205547400_CIT0014","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/acr.21568","article-title":"Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period","volume":"64","author":"Steiman","year":"2012","journal-title":"Arthritis Care & Research"},{"issue":"5","key":"2024110408205547400_CIT0015","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3899\/jrheum.140677","article-title":"Four Anti-dsDNA antibody assays in relation to systemic lupus erythematosus disease specificity and activity","volume":"42","author":"Enocsson","year":"2015","journal-title":"J Rheumatol."},{"issue":"9","key":"2024110408205547400_CIT0016","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"2024110408205547400_CIT0017","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1191\/0961203306lu2324oa","article-title":"Detection of antibodies to dsDNA: an overview of laboratory assays","volume":"15","author":"Rouquette","year":"2006","journal-title":"Lupus."},{"issue":"8","key":"2024110408205547400_CIT0018","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.autrev.2007.05.001","article-title":"AutoAbSC.Org \u2013 autoantibody standardization committee in 2006","volume":"6","author":"Chan","year":"2007","journal-title":"Autoimmun Rev."},{"issue":"9","key":"2024110408205547400_CIT0019","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/ard.47.9.740","article-title":"The first international standard for antibodies to double stranded DNA","volume":"47","author":"Feltkamp","year":"1988","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"2024110408205547400_CIT0020","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1136\/annrheumdis-2019-215845","article-title":"A WHO reference reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation","volume":"78","author":"Fox","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"2024110408205547400_CIT0021","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"2024110408205547400_CIT0022","doi-asserted-by":"crossref","first-page":"902821","DOI":"10.1155\/2015\/902821","article-title":"Clinical comparison of QUANTA Flash dsDNA Chemiluminescent Immunoassay with four current assays for the detection of anti-dsDNA autoantibodies","volume":"2015","author":"Infantino","year":"2015","journal-title":"J Immunol Res"},{"issue":"13-14","key":"2024110408205547400_CIT0023","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.cca.2010.03.016","article-title":"Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus","volume":"411","author":"Launay","year":"2010","journal-title":"Clin Chim Acta."},{"issue":"3","key":"2024110408205547400_CIT0024","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s12026-018-8992-9","article-title":"Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests","volume":"66","author":"Infantino","year":"2018","journal-title":"Immunol Res."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/6\/732\/60250709\/lmae035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/6\/732\/60250709\/lmae035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:22:25Z","timestamp":1730690545000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/55\/6\/732\/7683087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,27]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmae035","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,5,27]]}}}